RxDoctor Payments Data

Ronald Buhain

Internal Medicine · Ft Lauderdale, FLNPI 1548273295

Payments from drug & device makers

$2,456in general payments, 2019–2025

Across 92 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Amgen$556
  • Novo Nordisk$149
  • Pfizer$91
  • Biosense Webster, Inc.$59
  • Boston Scientific$53
  • plus $243 from 9 others

What the payments were for

  • Food & beverage$2,451100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,456 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$75,880
Medicare patients
361
Services billed
991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$124,069
OzempicSemaglutide87$91,130
XareltoRivaroxaban46$49,306
TivicayDolutegravir Sodium12$27,631
JardianceEmpagliflozin27$27,016
DescovyEmtricitabine/Tenofov Alafenam12$26,956
JanuviaSitagliptin Phosphate17$25,223
MounjaroTirzepatide24$24,838
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,280
SymbicortBudesonide/Formoterol Fumarate13$7,689
Atorvastatin Calcium644$6,705
SynthroidLevothyroxine Sodium52$4,264
Omeprazole252$4,080
Testosterone23$3,920
Rosuvastatin Calcium306$3,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$124,069133 claims
Novo NordiskOzempic$149$91,13087 claims
Johnson & JohnsonXarelto$1,305$49,30646 claims
Boehringer IngelheimJardiance$36$27,01627 claims
MerckJanuvia$11$25,22317 claims
Lilly USA, LLCMounjaro$15$24,83824 claims
GSKTrelegy Ellipta$14$9,28013 claims
AstraZenecaSymbicort$48$7,68913 claims
AbbVieSynthroid$14$4,26452 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Ft Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →